bpc 157 human clinical trials safety evidence bpc-157 review regulatory status Gastric pentadecapeptide body protection compound bpc-157 human clinical trials evidence
Description
One trial with 140 middle-aged volunteers showed dose-dependent increases in whole blood NAD+ levels after 8 weeks
As they are shorter than proteins, they enter the bloodstream more quickly
Genis-Mendoza, Alma Delia, et al
But at tiny doses, its like a gentle tap on the shoulder
It means that as a standalone oral therapy at the tested doses, it did not produce the magnitude of weight loss that pharmaceutical companies require for commercial viability
